The US Food and Drug Administration (FDA) has granted Philips 510(k) clearance for its AI-powered MRI platform suitable for the treatment of head and neck cancers.
The software enables clinicians to refine the planning of radiation therapy in soft tissue tumors of the head and neck. Additionally, the software eliminates the need for multiple imaging exams, including additional CT scans, by deriving CT-like images from a single MRI exam that can be completed in less than three minutes.
“The superior soft tissue imaging of MRI along with advances in data integration and orchestration, including the use of artificial intelligence, promise greater clarity and less subjectivity in planning. radiation therapy for head and neck cancer,” said Philips Medical Director for Oncology Solutions. , Ilya Gipp, MD, PhD, said in an Oct. 20 statement about the clearance.
AI-enabled MRCAT (MR for Calculating ATtenuation) also has applications for the treatment of brain, pelvic and prostate cancers, as it can help with dose calculations and patient positioning.
This last authorization was discussed at the American Society for Radiation Oncology 2022 Annual Meetingwhere Philips also shared its partnership with MacroMedics—a company specializing in patient positioning solutions for radiotherapy treatments.